贝伐单抗治疗非小细胞肺癌患者高血压的发病率及风险：一项随机对照试验的荟萃分析

Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials.

作者信息

Chen Jian, Lu Yingfeng, Zheng Yunliang

机构信息

Intensive Care Unit, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.

出版信息

Drug Des Devel Ther. 2015 Aug 18;9:4751-60. doi: 10.2147/DDDT.S87258. eCollection 2015.

AIM

A study was conducted to determine the overall risk and incidence of hypertension with bevacizumab in non-small-cell lung cancer (NSCLC) patients.

MATERIALS AND METHODS

Electronic databases such as the Embase, PubMed, and Cochrane Library were searched for related trials. Statistical analyses were conducted to calculate the overall incidence rates, odds ratios (ORs), and 95% confidence intervals (CIs) by using either random-effect or fixed-effect models depending on the heterogeneity.

RESULTS

A total of 3,155 subjects from nine studies were included. The overall incidences of all-grade and high-grade hypertension in NSCLC patients were 19.55% (95% CI 10.17%-34.3%) and 6.95% (95% CI 5.81%-8.30%). Bevacizumab use was associated with a significantly increased risk in all-grade hypertension (OR 8.07, 95% CI 3.87-16.85; P=0.0002) and high-grade hypertension (OR 5.93, 95% CI 3.41-10.32; P<0.0001). No evidence of publication bias was determined for the ORs of hypertension in our meta-analysis.

CONCLUSION

Bevacizumab is associated with a significantly increased risk of hypertension development in NSCLC patients. Early monitoring and effective management of hypertension might be important steps for the safe use of this drug.

目的

开展一项研究以确定贝伐单抗用于非小细胞肺癌（NSCLC）患者时高血压的总体风险及发生率。

材料与方法

检索Embase、PubMed和Cochrane图书馆等电子数据库以查找相关试验。根据异质性采用随机效应或固定效应模型进行统计分析，以计算总体发生率、比值比（OR）和95%置信区间（CI）。

结果

共纳入来自9项研究的3155名受试者。NSCLC患者中所有级别和高级别高血压的总体发生率分别为19.55%（95%CI 10.17%-34.3%）和6.95%（95%CI 5.81%-8.30%）。使用贝伐单抗与所有级别高血压（OR 8.07，95%CI 3.87-16.85；P=0.0002）和高级别高血压（OR 5.93，95%CI 3.41-10.32；P<0.0001）的风险显著增加相关。在我们的荟萃分析中，未确定高血压OR存在发表偏倚的证据。